innovations in surgical oncology

35
Innovations in Surgical Oncology Innovations in Surgical Oncology Sricharan Chalikonda, M.D. Surgical Oncology Director Gen.Surg Robotics Program Cleveland Clinic Sricharan Chalikonda, M.D. Surgical Oncology Director Gen.Surg Robotics Program Cleveland Clinic

Upload: others

Post on 12-Sep-2021

6 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Innovations in Surgical Oncology

Innovations in Surgical OncologyInnovations in Surgical Oncology

Sricharan Chalikonda, M.D.Surgical Oncology

Director Gen.Surg Robotics ProgramCleveland Clinic

Sricharan Chalikonda, M.D.Surgical Oncology

Director Gen.Surg Robotics ProgramCleveland Clinic

Page 2: Innovations in Surgical Oncology

DisclosuresDisclosures

CovidienSpeaker

BardSpeaker

Intuitive SurgicalProctorSpeaker

CovidienSpeaker

BardSpeaker

Intuitive SurgicalProctorSpeaker

Page 3: Innovations in Surgical Oncology

Surgical Oncology ProgramsSurgical Oncology Programs

CarcinomatosisHIPEC

SarcomaResection with HAM catheters

Minimally Invasive/Robotic Approaches

CarcinomatosisHIPEC

SarcomaResection with HAM catheters

Minimally Invasive/Robotic Approaches

Page 4: Innovations in Surgical Oncology

Peritoneal CarcinomatosisPeritoneal Carcinomatosis

Progressive involvement of peritoneal surfaces by tumor seeded within peritoneal cavity

Rupture primary tumorSpillage tumor cells by surgical manipulation

Traditionally considered Stage IV diseaseTreated with systemic chemotherapySurgical treatment palliative for sympotomatic disease

Progressive involvement of peritoneal surfaces by tumor seeded within peritoneal cavity

Rupture primary tumorSpillage tumor cells by surgical manipulation

Traditionally considered Stage IV diseaseTreated with systemic chemotherapySurgical treatment palliative for sympotomatic disease

Page 5: Innovations in Surgical Oncology

Gastric~11,000

Colon~17,000

Appendiceal~1100

Ovarian~20,000

Mesothelioma~500

Pseudomyxoma

Aggressiveness

Patient PopulationPatient Population

Page 6: Innovations in Surgical Oncology

Peritoneal Carcinomatosis-Natural History-

Peritoneal Carcinomatosis-Natural History-

Crampy abdominal painAnorexia/Weight lossBowel ObstructionAscitesInanitionInfectionDeath

Crampy abdominal painAnorexia/Weight lossBowel ObstructionAscitesInanitionInfectionDeath

Page 7: Innovations in Surgical Oncology

Major problem in cancer management

Hard to detect by imagingDifficult to manageMarked deterioration in quality of life Short survival

Major problem in cancer management

Hard to detect by imagingDifficult to manageMarked deterioration in quality of life Short survival

Peritoneal CarcinomatosisPeritoneal Carcinomatosis

Page 8: Innovations in Surgical Oncology

Treatment OptionsTreatment OptionsSurgical Treatment

Surgery with or without systemic chemotherapy has shown to be inadequate for the treatment of patients with PC.

Systemic ChemotherapyPoor penetration to peritoneum

Peritoneal Chemo Dwell

Surgical TreatmentSurgery with or without systemic chemotherapy has shown to be inadequate for the treatment of patients with PC.

Systemic ChemotherapyPoor penetration to peritoneum

Peritoneal Chemo Dwell

Page 9: Innovations in Surgical Oncology

Rationale: Cyto-Surgery + HIPEC Rationale: Cyto-Surgery + HIPEC

Cancer is confined to peritoneal cavitySurgeon can take down adhesions, cytoreduce tumorsHeat has effect on cancer cells“Targeting” and localizing the principal effect of a multi-modality treatment

Cancer is confined to peritoneal cavitySurgeon can take down adhesions, cytoreduce tumorsHeat has effect on cancer cells“Targeting” and localizing the principal effect of a multi-modality treatment

Page 10: Innovations in Surgical Oncology

Multi-Modality TreatmentMulti-Modality Treatment

CYTOREDUCTIVESURGERY

INTRAPERITONEAL HYPERTHERMIA

CHEMOTHERAPY

Page 11: Innovations in Surgical Oncology

Verwaal et al. 2003

Page 12: Innovations in Surgical Oncology

Verwaal et al. 2003

Page 13: Innovations in Surgical Oncology
Page 14: Innovations in Surgical Oncology

Improve SurvivalImprove SurvivalPeritonealCancer

Average Life expectancy with standard therapy

With “HIPEC”

Colon 6 mos. 18 – 36 mos.

AppendixPMP

10 mos.5 -10 yrs.

30 mos.10 – 20 yrs.

Mesothelioma 12 – 21 mos. 34 – 92 mos.

Ovarian 6 mos. 25 – 28 mos.

Gastric 1 mos. 14 – 24 mos.

Page 15: Innovations in Surgical Oncology

Before/After Cytoreductive Surgery

Before/After Cytoreductive Surgery

Page 16: Innovations in Surgical Oncology
Page 17: Innovations in Surgical Oncology

Cytoreductive SurgeryCytoreductive Surgery

The first and most important stepThe goal is to remove all visible disease.This would leave microscopic and small surface tumors.

The first and most important stepThe goal is to remove all visible disease.This would leave microscopic and small surface tumors.

Page 18: Innovations in Surgical Oncology
Page 19: Innovations in Surgical Oncology
Page 20: Innovations in Surgical Oncology
Page 21: Innovations in Surgical Oncology
Page 22: Innovations in Surgical Oncology
Page 23: Innovations in Surgical Oncology
Page 24: Innovations in Surgical Oncology

Approach to Patients with Peritoneal CarcinomatosisApproach to Patients with Peritoneal Carcinomatosis

Recommend Biopsy of nodules and peritoneal washingsNo need to resect primary unless perforatedNeoadjuvant chemo followed by cytoreductive surgery with HIPEC if possible

Recommend Biopsy of nodules and peritoneal washingsNo need to resect primary unless perforatedNeoadjuvant chemo followed by cytoreductive surgery with HIPEC if possible

Page 25: Innovations in Surgical Oncology

Retroperitoneal SarcomaRetroperitoneal Sarcoma

Usually grow to a large size before presentationRequire multivisceral resection to remove completelyHigh recurrence rate

Usually grow to a large size before presentationRequire multivisceral resection to remove completelyHigh recurrence rate

Page 26: Innovations in Surgical Oncology

Treatment OptionsTreatment Options

Neoadjuvant radiation followed by resection

Bowel and other structures protected by tumorDifficult to focus on margin

Resection followed by radiationBowel exposed to radiation which limits dose

Neoadjuvant radiation followed by resection

Bowel and other structures protected by tumorDifficult to focus on margin

Resection followed by radiationBowel exposed to radiation which limits dose

Page 27: Innovations in Surgical Oncology

Resection with periop radiationResection with periop radiation

Tumor resectedBowel packed awayCatheters placed at margin and radiation administered over next 36hoursComplete treatment achieved during one hospitalization

Tumor resectedBowel packed awayCatheters placed at margin and radiation administered over next 36hoursComplete treatment achieved during one hospitalization

Page 28: Innovations in Surgical Oncology

Case reportCase report

60 year old with abdominal fullness and vague pain

60 year old with abdominal fullness and vague pain

Page 29: Innovations in Surgical Oncology

Surgical ResectionSurgical Resection

ColectomyNephrectomyCholecystectomyPlacement of Catheters

ColectomyNephrectomyCholecystectomyPlacement of Catheters

Page 30: Innovations in Surgical Oncology

ResultResult

Page 31: Innovations in Surgical Oncology

RoboticsRobotics

Page 32: Innovations in Surgical Oncology

Robotic Liver ResectionRobotic Liver Resection

Page 33: Innovations in Surgical Oncology

Pancreatic SurgeryPancreatic Surgery

Page 34: Innovations in Surgical Oncology

Biliary DissectionBiliary Dissection

55 Year old female with abdominal pain. Found to have choledochol cyst during routine IOC.

55 Year old female with abdominal pain. Found to have choledochol cyst during routine IOC.

Page 35: Innovations in Surgical Oncology

Thank YouThank YouStaff

Lisa TaylorSue DreesNancy Brown

PartnersMatt WalshBob PelleyPedro EscobarChad MichenerPeter RoseRich DrakeKevin Stephans

StaffLisa TaylorSue DreesNancy Brown

PartnersMatt WalshBob PelleyPedro EscobarChad MichenerPeter RoseRich DrakeKevin Stephans